Benefit-Risk Assessment Based on Ordered Clinical Outcomes

被引：0
|
作者：
Caster, Ola [1 ,2 ]
Noren, G. Niklas [1 ]
Ekenberg, Love [2 ]
Edwards, I. Ralph [1 ]
机构：
[1] WHO Collaborating Ctr Int Drug Monitoring, Uppsala, Sweden
[2] Stockholm Univ, Dept Comp & Syst Sci, Stockholm, Sweden
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2010年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
17
引用
收藏
页码：S8 / S8
页数：1
相关论文
共 50 条
  • [31] A benefit-risk assessment of caffeine as an analgesic adjuvant
    Zhang, WY
    DRUG SAFETY, 2001, 24 (15) : 1127 - 1142
  • [32] Benefit-risk assessment for binary diagnostic tests
    Bai, Tianyu
    Huang, Lan
    Li, Meijuan
    Tiwari, Ram
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2019, 29 (05) : 760 - 775
  • [33] Benefit-risk assessment of rofecoxib in the treatment of osteoarthritis
    Schmidt, H
    Woodcock, BG
    Geisslinger, G
    DRUG SAFETY, 2004, 27 (03) : 185 - 196
  • [34] Benefit-Risk Assessment of Rofecoxib in the Treatment of Osteoarthritis
    Helmut Schmidt
    Barry G. Woodcock
    Gerd Geisslinger
    Drug Safety, 2004, 27 : 185 - 196
  • [35] Bayesian Approach to Personalized Benefit-Risk Assessment
    Cui, Shiqi
    Zhao, Yueqin
    Tiwari, Ram C.
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2016, 8 (03): : 316 - 324
  • [36] Benefit-Risk Assessment of Sirolimus in Renal Transplantation
    Dirk R.J. Kuypers
    Drug Safety, 2005, 28 : 153 - 181
  • [37] Benefit-risk assessment of sirolimus in renal transplantation
    Kuypers, DRJ
    DRUG SAFETY, 2005, 28 (02) : 153 - 181
  • [38] A benefit-risk assessment of basiliximab in renal transplantation
    Boggi, U
    Danesi, R
    Vistoli, F
    Del Chiaro, M
    Signori, S
    Marchetti, P
    Del Tacca, M
    Mosca, F
    DRUG SAFETY, 2004, 27 (02) : 91 - 106
  • [39] Benefit-risk assessment of zaleplon in the treatment of insomnia
    Barbera, J
    Shaprio, C
    DRUG SAFETY, 2005, 28 (04) : 301 - 318
  • [40] Benefit-risk assessment of antileukotrienes in the management of asthma
    García-Marcos, L
    Schuster, A
    Pérez-Yarza, EG
    DRUG SAFETY, 2003, 26 (07) : 483 - 518
12345